Evidence map›Paper›PMID 41425554›Full record

ArticleFrontiers in immunology2025

Conformational stability of hemocyanins regulates their lysosomal and proteasomal degradation, influencing their pro-inflammatory effects on mammalian antigen-presenting cells.

Michelle L Salazar, Claudia d'Alençon, Diego Díaz-Dinamarca, Javier Bustamante, Byron Castillo, Alejandra Alvarado, Fabián Salazar, Augusto Manubens, María Inés Becker

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michelle L SalazarFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Claudia d'AlençonFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Diego Díaz-DinamarcaFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Javier BustamanteFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Byron CastilloFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Alejandra AlvaradoFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Fabián SalazarFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
Augusto ManubensFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.
María Inés BeckerFundación Ciencia y Tecnología para el Desarrollo (FUCITED), Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mollusk hemocyanins are known for their immunomodulatory properties in mammals. Their applications include serving as carrier glycoproteins, functioning as protein-based adjuvants, and acting as non-specific immunostimulants in cancer vaccine strategies. Their immunomodulatory effects are attributed to their xenogenicity, structural complexity, high molecular mass, and glycosylations. Recent studies have begun to clarify the immunological mechanisms by which hemocyanins induce: multiligand properties arising from interactions with C-type lectins and Toll-like receptors, and the promotion of a Th1 immune response. However, the subsequent effects of hemocyanins, particularly their intracellular targeting and degradation kinetics, remain poorly understood. The present study is the first to comprehensively examine the processing of two well-characterized hemocyanins, known for their conformational stability and clinical significance: KLH from Methods: We correlated their degradation with the kinetics of the proinflammatory response they induce and their subcellular localization using the JAWS II cell line and bone marrow-derived dendritic cells (BMDCs). We utilize OVA to highlight the differences between this protein and the hemocyanins. Results: The results showed that KLH and CCH induced significant TNF levels after 24 hours and also promoted the secretion of IL-6 and IL-12p40 after 96 hours, along with the upregulation of CD80 and CD86. This delayed response corresponds with their slow intracellular degradation. Colocalization studies using LAMP-1 demonstrated that hemocyanins were localized to lysosomes only after prolonged stimulation, suggesting that they are likely stored in intracellular depots. Furthermore, hemocyanins were shown to colocalize with LMP-2 and a4, indicating that they undergo processing in the proteasome. In contrast, OVA displayed faster degradation with mild pro-inflammatory effects within 24 hours. Pharmacological inhibition of lysosomal cathepsins or the proteasome reduced the hemocyanin-dependent secretion of IL-6 and IL-12p40. Additionally, fragmented hemocyanins led to lower, less sustained cytokine levels compared to their native form. Conclusions: These findings emphasize that hemocyanins, owing to their complex oligomeric structure and high stability, are slowly processed by APCs, thereby contributing to their immunogenicity. This property is particularly relevant when hemocyanins are used as carriers for vaccine antigens because their delayed kinetics can enhance the magnitude, quality, and persistence of responses.

Indexed as

Antigen-Presenting CellsDendritic CellsHemocyaninsLysosomesProteasome Endopeptidase ComplexAnimalsCell LineCytokinesInflammationMiceProtein ConformationProtein StabilityProteolysisCytokinesHemocyaninsProteasome Endopeptidase Complexantigen-presenting cellshemocyaninsimmunomodulationimmunoproteasomeintracellular degradationlysosomeoligomeric glycoproteinsprotein based-adjuvant

Identifiers

PMID41425554
PMCPMC12715429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.